VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy

Gene Therapy

Volumn 17, Issue 7, 2010, Pages 922-929

  Eshun, F K ^a   Currier, M A ^a   Gillespie, R A ^a   Fitzpatrick, J L ^a   Baird, W H ^a,b   Cripe, T P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

antiangiogenesis; Ewing's sarcoma; HSV; oncolytic virotherapy; rhabdomyosarcoma; VEGF

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY DC101; ONCOLYTIC HERPES VIRUS; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; ONCOLYTIC VIRUS; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; DRUG ANTAGONISM; EWING SARCOMA; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RHABDOMYOSARCOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PROCEDURES; SARCOMA, EWING; SIMPLEXVIRUS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SIMPLEXVIRUS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS; ANTIBODIES, MONOCLONAL, HUMANIZED; SARCOMA, EWING;

HERPESVIRIDAE; MUS; SIMPLEXVIRUS;

EID: 77954540082     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.82     Document Type: Article

References (44)

1. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma 2000; 4: 103-112.
2. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995; 13: 2123-2139.
3. Ries L, Smith M, Gurney J, Linet M, Tamra T, Young J et al. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995, NIH Pub. No.99-46491999: National Cancer Institute, SEER Program: Bethesda, MD.
4. Pratt C, Maurer H, Gieser P, Salzberg A, Rao B, Parham D et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: A Pediatric Oncology Group study. Med Pediatr Oncol 1998; 30: 201-209.
5. Goldsby R, Burke C, Nagarajan R, Zhou T, Chen Z, Marina N et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort. Cancer 2008; 113: 2597-2604.
6. Miser JS, Goldsby RE, Chen Z, Krailo MD, Tarbell NJ, Link MP et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy\a report from the Children's Oncology Group. Pediatr Blood Cancer 2007; 49: 894-900.
7. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another. Expert Opin Investig Drugs 2000; 9: 311-327.
8. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007; 99: 1768-1781.
9. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncoly-tic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999; 59: 3861-3865.
10. Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophos-phamide. Mol Ther 2008; 16: 879-885.
11. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992; 52: 5110-5114.
12. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380.
13. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000; 60: 4251-4255.
14. Duda DG. Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res 2006; 66: 3967-3970.
15. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-3736.
16. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-3950.
17. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.
18. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Therapy 1999; 6: 1336-1339.
19. Schellingerhout D, Bogdanov Jr A, Marecos E, Spear M, Breakefield X, Weissleder R. Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther 1998; 9: 1543-1549.
20. Oyama M, Ohigashi T, Hoshi M, Nakashima J, Tachibana M, Murai M et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000; 11: 1683-1693.
21. Cinatl Jr J, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel J-U et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 2003; 63: 1508-1514.
22. Fu X, Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res 2002; 62: 2306-2312.
23. Wong R, Chan M-K, Yu Z, Kim T, Bhargava A, Stiles B et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10: 251-259.
24. Nakamori M, Fu X, Pettaway C, Zhang X. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 2004; 60: 53-60.
25. Delman KA, Bennett JJ, Zager JS, Burt BM, McAuliffe PF, Petrowsky H et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000; 11: 2465-2472.
26. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17: 1214-1224.
27. Fong Y, Kim T, Bhargava A, Schwartz L, Brown K, Brody L et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 2009; 17: 389-394.
28. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155-7165.
29. Duerner LJ, Schwantes A, Schneider IC, Cichutek K, Buchholz CJ. Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue. Gene Ther 2008; 15: 1500-1510.
30. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res 2007; 67: 9371-9379.
31. Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999; 5: 881-887.
32. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74: 4765-4775.
33. Wakimoto H, Ikeda K, Abe T, Ichikawa T, Hochberg FH, Ezekowitz RA et al. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 2002; 5: 275-282.
34. Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 2008; 16: 1910-1918.
35. Power AT, Bell JC. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007; 15: 660-665.
36. Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 2008; 16: 1217-1226.
37. Allen T, Cullis P. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-1822.
38. Gimenez-Cassina A, Lim F, Diaz-Nido J. Differentiation of a human neuroblastoma into neuron-like cells increases their susceptibility to transduction by herpesviral vectors. J Neurosci Res 2006; 84: 755-767.
39. Yu Z, Li S, Huang YY, Fong Y, Wong RJ. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma. Cancer Gene Ther 2007; 14: 738-747. (Pubitemid 47080363)
40. Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-1986.
41. Benencia F, Courreges MC, Conejo-Garcia JR, Buckanovich RJ, Zhang L, Carroll RH et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005; 16: 765-778.
42. Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004; 64: 6616-6625.
43. Sharp R, Recio J, Jhappan C, Otsuka T, Liu S, Yu W et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002; 8: 1276-1280.
44. Tong R, Boucher Y, Kozin S, Winkler F, Hicklin D, Jain R. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-3736.